{"task_id": "54ac15ea8a24d3c1", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 320/464)", "text": "g IV, no faster than 50 mg/min, start\n310\nSeizures\n\n--- Page 332 ---\nMANAGEMENT (CONT\u2019D)\ncontinuous\nmonitor),\nthird\nline\n(midazolam\n0.05 0.3 mg/kg over 20 30 s, repeat PRN), fourth\nline (anesthetic doses of propofol 50 100 mg IV\nbolus, need for intubation). Note: phenytoin and\nbenzodiazepines are incompatible in IV tubing and\nwill precipitate if infused in same line. Use separate IV\nsites. See p. 101 for treatment of rhabdomyolysis\nACUTE SEIZURE CONTROL\nbenzodiazepines (lor\nazepam 1 mg IV/SL PRN, up to a total dose of 0.1 mg/\nkg. Diazepam 10 mg PO q6h and 5 mg PO q2h PRN).\nAntiepileptic (fosphenytoin 20 mg/kg IV, phenytoin\n300 mg IV over 10 min, phenobarbital, carbamaze\npine, valproate). If alcohol withdrawal (add thiamine\n100 mg IV/PO daily, multi vitamin 1 tab IV/PO daily)\nLONG TERM\nMANAGEMENT\nvalproic\nacid\n200 500 mg or 10 15 mg/kg PO daily, increase\ndose by 250 500 mg/week, typical daily dose is\n750 2000 mg; lamotrigine 25 mg PO daily, increase\ndose\nby\n25\nmg/week,\ntypical\ndaily\ndose\nis\n100 400 mg; topiramate 25 50 mg PO daily, increase\nby 25 50 mg/week, typical daily dose is 200 400 mg;\nlevetiracetam 250 500 mg PO daily, increase dose by\n250 500\nmg/week,\ntypical\ndaily\ndose\nis\n1000 3000 mg; carbamazepine 200 mg PO daily,\nincrease by 200 mg every 3 days, typical daily dose\nis 400 800 mg; phenytoin 3 5 mg/kg PO daily (load\ning dose may be given for quicker effect), typical daily\ndose is 200 400 mg; gabapentin 300 mg daily BID,\nincrease dose by 300 600 mg/week, typical daily\ndose is 1800 3600 mg; pregabalin 75 150 mg PO\ndaily, increase dose by 75 150 mg/week, typical\ndaily dose is 150 300 mg\nPSYCHOSOCIAL ASPECTS\nloss of independence,\nemployment, insurance, self esteem, and ability to\ndrive\nDRIVING\nISSUES\nrecommendations\nvary\nfrom\nregion to region. Check with driving authority for\nspecific restrictions and legal requirements. If single\nunprovoked seizure, usually no driving restrictions\nare needed as long as EEG and imaging are normal.\nIf >1 unprovoked seizure, consider 6 12 months of\nseizure free\ninterval\nbefore\nre instating\ndriver\u2019s\nlicense (varies with jurisdiction). Some places may\nalso restrict driving for 6 months after antiepileptic\ndose adjustments. More stringent rules may exist for\ncommercial drivers\nTREATMENT ISSUES\nFIRST TIME SEIZURE\nif no structural lesion, no\nphysical findings, and normal EEG, usually do not\nneed to start antiseizure medications. Risk of\nTREATMENT ISSUES (CONT\u2019D)\nrecurrence after first seizure is 30 60%. Risk after\nsecond seizure is 80 90%\nANTIEPILEPTIC CHOICES\n\u0002\nBROAD-SPECTRUM ANTIEPILEPTIC DRUGS\nin decreas\ning order of efficacy, include valproic acid, lamo\ntrigine, topiramate, levetiracetam, and zonisamide.\nThese antiepileptic medications represent reason\nable first line therapy for most seizure types\n\u0002\nNARROW-SPECTRUM ANTIEPILEPTIC DRUGS\ninclude\ncarbamazepine, phenytoin, gabapentin, tiaga\nbine, oxcarbazepine, and pregabalin. These med\nications are effective against partial seizures\nwith or without secondarily generalized features,\nbut have limited activity against primary general\nized seizures\nP\nC\nV\nB\nL\nG\nT\nE\nTonic clonic\n+\n+\n1\n+\n+\n\u0004\nAbsence\n+\n1\nStatus\n+\n+\nPartial\n+\n1\n+\n+\n\u0004\n+\nMyoclonic\n+\n+\nKey: P=phenytoin, C=carbamazepine, V=valproate,\nB=phenobarbital, L=lamotrigine, G=gabapentin,\nT=levetiracetam or topiramate, E=ethosuximide,\n1=drug of choice, +=possible use, \u0004=adjunct use\nSTOPPING\nANTIEPILEPTICS\nconsider\nstopping\nanticonvulsants after a seizure free period of 2 5\nyears. Relapse is 26 63% within 1 2 years after with\ndrawal. Risk factors for recurrence include abnormal\nEEG before or during withdrawal, abnormal neurolo\ngic findings, frequent seizures before remission, and\nmental retardation\nDRUG\nOR TOXIN INDUCED SEIZURES\ntop five\ndrug induced etiologies include isoniazide, theophyl\nline, oral hypoglycemic agents, carbon monoxide,\nand bupropion. Supportive management for theo\nphylline induced, carbon monoxide induced, and\nbupropion induced\nseizures.\nTreat\nisoniazide\ninduced seizures with pyridoxine; hypoglycemic sei\nzures with glucose \u0004 octreotide and glucagon; and\ncarbon monoxide associated seizures with oxygen\n(hyperbaric oxygen controversial)\nRelated Topics\nBrain Tumors (p. 297)\nSeizures in Pregnancy (p. 415)\nToxicology (p. 102)\nSeizures\n311", "text_length": 4254, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 320/464)", "type": "chunk", "chunk_index": 319, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.686952", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.687723", "status": "complete", "chunks_added": 3}